These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
492 related articles for article (PubMed ID: 12937692)
1. [PET with (18)F-fluorodeoxyglucose for staging of non-small cell lung cancer]. Weber WA; Dietlein M; Hellwig D; Kirsch CM; Schicha H; Schwaiger M Nuklearmedizin; 2003 Aug; 42(4):135-44. PubMed ID: 12937692 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study. Verboom P; van Tinteren H; Hoekstra OS; Smit EF; van den Bergh JH; Schreurs AJ; Stallaert RA; van Velthoven PC; Comans EF; Diepenhorst FW; van Mourik JC; Postmus PE; Boers M; Grijseels EW; Teule GJ; Uyl-de Groot CA; Eur J Nucl Med Mol Imaging; 2003 Nov; 30(11):1444-9. PubMed ID: 14579081 [TBL] [Abstract][Full Text] [Related]
3. The additional value of FDG PET imaging for distinguishing N0 or N1 from N2 stage in preoperative staging of non-small cell lung cancer in region where the prevalence of inflammatory lung disease is high. Turkmen C; Sonmezoglu K; Toker A; Yilmazbayhan D; Dilege S; Halac M; Erelel M; Ece T; Mudun A Clin Nucl Med; 2007 Aug; 32(8):607-12. PubMed ID: 17667432 [TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients. Wu Y; Li P; Zhang H; Shi Y; Wu H; Zhang J; Qian Y; Li C; Yang J Int J Cancer; 2013 Jan; 132(2):E37-47. PubMed ID: 22890912 [TBL] [Abstract][Full Text] [Related]
5. Mediastinal staging in Non-Small-Cell Lung Carcinoma: computed tomography versus F-18-fluorodeoxyglucose positron-emission tomography and computed tomography. Harders SW; Madsen HH; Hjorthaug K; Arveschoug AK; Rasmussen TR; Meldgaard P; Hoejbjerg JA; Pilegaard HK; Hager H; Rehling M; Rasmussen F Cancer Imaging; 2014 Jun; 14(1):23. PubMed ID: 25608616 [TBL] [Abstract][Full Text] [Related]
6. Lymph node staging in non-small cell lung cancer: evaluation by [18F]FDG positron emission tomography (PET). Guhlmann A; Storck M; Kotzerke J; Moog F; Sunder-Plassmann L; Reske SN Thorax; 1997 May; 52(5):438-41. PubMed ID: 9176535 [TBL] [Abstract][Full Text] [Related]
7. Stage T1 non-small cell lung cancer: preoperative mediastinal nodal staging with integrated FDG PET/CT--a prospective study. Kim BT; Lee KS; Shim SS; Choi JY; Kwon OJ; Kim H; Shim YM; Kim J; Kim S Radiology; 2006 Nov; 241(2):501-9. PubMed ID: 16966480 [TBL] [Abstract][Full Text] [Related]
8. Is FDG PET/CT cost-effective for pre-operation staging of potentially operative non-small cell lung cancer? - From Chinese healthcare system perspective. Wang YT; Huang G Eur J Radiol; 2012 Aug; 81(8):e903-9. PubMed ID: 22698711 [TBL] [Abstract][Full Text] [Related]
9. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Shim SS; Lee KS; Kim BT; Chung MJ; Lee EJ; Han J; Choi JY; Kwon OJ; Shim YM; Kim S Radiology; 2005 Sep; 236(3):1011-9. PubMed ID: 16014441 [TBL] [Abstract][Full Text] [Related]
10. Accuracy and cost-effectiveness of [18F]-2-fluoro-deoxy-D-glucose-positron emission tomography scan in potentially resectable non-small cell lung cancer. Kelly RF; Tran T; Holmstrom A; Murar J; Segurola RJ Chest; 2004 Apr; 125(4):1413-23. PubMed ID: 15078754 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of strategies introducing integrated ¹⁸F-FDG PET/CT into the mediastinal lymph node staging of non-small-cell lung cancer. Han Y; Xiao H; Zhou Z; Yuan M; Zeng Y; Wu H; Fang Y Nucl Med Commun; 2015 Mar; 36(3):234-41. PubMed ID: 25460305 [TBL] [Abstract][Full Text] [Related]
12. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. Gambhir SS; Hoh CK; Phelps ME; Madar I; Maddahi J J Nucl Med; 1996 Sep; 37(9):1428-36. PubMed ID: 8790186 [TBL] [Abstract][Full Text] [Related]
13. Value of positron emission tomography for lung cancer staging. Albes JM; Dohmen BM; Schott U; Schülen E; Wehrmann M; Ziemer G Eur J Surg Oncol; 2002 Feb; 28(1):55-62. PubMed ID: 11869015 [TBL] [Abstract][Full Text] [Related]
14. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography. Billé A; Pelosi E; Skanjeti A; Arena V; Errico L; Borasio P; Mancini M; Ardissone F Eur J Cardiothorac Surg; 2009 Sep; 36(3):440-5. PubMed ID: 19464906 [TBL] [Abstract][Full Text] [Related]
15. Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease. Farrell MA; McAdams HP; Herndon JE; Patz EF Radiology; 2000 Jun; 215(3):886-90. PubMed ID: 10831716 [TBL] [Abstract][Full Text] [Related]
16. PET versus PET/CT dual-modality imaging in evaluation of lung cancer. Freudenberg LS; Rosenbaum SJ; Beyer T; Bockisch A; Antoch G Radiol Clin North Am; 2007 Jul; 45(4):639-44, v. PubMed ID: 17706528 [TBL] [Abstract][Full Text] [Related]
18. [Impact of positron emission tomography on clinical management of potentially resectable non-small-cell lung cancer: a French prospective multicenter study]. Margery J; Milleron B; Vaylet F; Grahek D; Lebeau B; Mangiapan G; Bonardel G; de Labriolle-Vaylet C; Meignan M; Carette MF; Talbot JN; Housset B Rev Pneumol Clin; 2010 Oct; 66(5):313-20. PubMed ID: 21087727 [TBL] [Abstract][Full Text] [Related]
19. [Contribution of PET using FDG in the diagnosis of lung cancer--first results]. Rubinstein R; Breuer R; Chisin R Harefuah; 2001 Feb; 140(2):100-3, 191. PubMed ID: 11242909 [TBL] [Abstract][Full Text] [Related]
20. Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Steinert HC; Hauser M; Allemann F; Engel H; Berthold T; von Schulthess GK; Weder W Radiology; 1997 Feb; 202(2):441-6. PubMed ID: 9015071 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]